The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II trial of MM-121 in combination with erlotinib in patients (pts) with non-small cell lung cancer (NSCLC).
L. V. Sequist
Research Funding - Merrimack
W. A. Harb
Research Funding - Merrimack
M. Modiano
Research Funding - Merrimack
D. M. Jackman
Consultant or Advisory Role - Foundation Medicine
Research Funding - Merrimack
K. Wong
Research Funding - Merrimack
J. A. Engelman
Research Funding - Merrimack
R. Nering
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
M. Onsum
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack
V. M. Moyo
Employment or Leadership Position - Merrimack
Stock Ownership - Merrimack